The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.
Iron and Alzheimer’s Disease: An Update on Emerging Mechanisms
Abstract
Iron is a crucial transition metal for life and is the most abundant transition metal in the brain. However, iron's biological utility as an effective redox cycling metal also endows it with the potential to catalyze production of noxious free radicals. This "Janus-faced" nature of iron demands a tight regulation of cellular its metabolism. This regulation is crucial in the CNS, where iron plays myriad keystone roles in CNS processes, including mitochondrial energy transduction, enzyme catalysis, mitochondrial function, myelination, neurotransmitter anabolism and catabolism. Aberrations in brain iron homeostasis can elevate levels of this redox-active metal, leading to mislocalization of the metal and catastrophic oxidative damage to sensitive cellular and subcellular structures. Iron dyshomeostasis has been strongly linked to the pathogenesis of Alzheimer's disease (AD), as well as other major neurodegenerative diseases. Despite the growing societal burden of AD, no disease-modifying therapy exists, necessitating continued investment into both drug-development and the fundamental science investigating the disease-causing mechanisms. Targeting iron dyshomeostasis in the brain represents a rational approach to treat the underlying disease. Here we provide an update on known and emerging iron-associated mechanisms involved in AD. We conclude with an overview of evidence suggesting that, in addition to apoptosis, neuronal loss in AD involves "ferroptosis", a newly discovered iron- and lipid-peroxidation-dependent form of regulated necrosis. The ferroptosis field is rapidly progressing and may provide key insights for future drug-development with disease-modifying potential in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–205 of 205
Detecting Amyloid-β Plaques in Alzheimer’s Disease
Baltes, C., Princz-Kranz, F. L., Rudin, M., & Mueggler, T. (2010) · Methods in molecular biology · doi:10.1007/978-1-61737-992-5_26 · Cited by 22
Isolation of a phosphorylated soluble Tau fraction from Alzheimer's disease brain
Ledesma, M. D. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00075-p · Cited by 22
Effect of ascorbate in the reduction of transferrin-associated iron in endocytic vesicles
Escobar, A., Gaete, V., & Núñez, M. T. (1992) · Journal of Bioenergetics and Biomembranes · doi:10.1007/bf00762681 · Cited by 21
The Role of Presenilin in Protein Trafficking and Degradation—Implications for Metal Homeostasis
Greenough, M. A. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0826-4 · Cited by 20
Isaac, G., Fredriksson, A., Danielsson, R., Eriksson, P., & Bergquist, J. (2006) · FEBS Journal · doi:10.1111/j.1742-4658.2006.05236.x · Cited by 8
Cited by
Ferroptosis: past, present and future
Li, J., Cao, F., Yin, H.-L., Huang, Z.-J., Lin, Z.-T., Mao, N., Sun, B., & Wang, G. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2298-2 · Cited by 4,171
GPX4 at the crossroads of lipid homeostasis and ferroptosis
Forcina, G. C., & Dixon, S. J. (2019) · PROTEOMICS · doi:10.1002/pmic.201800311 · Cited by 1,025
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Nrf2 and Ferroptosis: A New Research Direction for Neurodegenerative Diseases
Song, X., & Long, D. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00267 · Cited by 577
Kent, S. A., Spires-Jones, T. L., & Durrant, C. S. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02196-w · Cited by 446
Metadata
- Authors
- Lane, D. J. R., Ayton, S., & Bush, A. I.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S379-S395
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2806462749
- Cited by
- 276
- References
- 205
- FWCI
- 16.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.